Search Weight Loss Topics:




Jul 7

Not Everyone Loses Weight on Ozempic – WIRED

Lose Weight Comments Off on Not Everyone Loses Weight on Ozempic – WIRED

Its not clear why some people on these drugs lose a lot of weight while others dont lose any. We still dont understand most of the variation in response, says Ewan Pearson, professor of diabetic medicine at the University of Dundee in Scotland. There are a few known predictors of how patients will fare, though. For instance, women tend to lose more weight than men on GLP-1 drugs, possibly because they have a different fat distribution compared to men, or because their smaller average size could mean higher exposure to the drug.

And while GLP-1 drugs were first approved as a diabetes treatment to improve blood sugar levels, theyre less likely to produce significant weight loss in people with type 2 diabetes. Researchers have suggested genetics, altered microbiomes, and other medications that promote weight gain as possible reasons for this. A lot depends on a persons physiology and biology. We cant expect that a drug will be a one-size-fits-all for everyone, says Amy Rothberg, an endocrinologist at the University of Michigan.

GLP-1 drugs lead to weight loss by slowing the movement of food in the stomach and by interacting with receptors in the brain to promote a feeling of fullness. Some people taking them report less food noisethey no longer have cravings or think about food all the time. As a result, they eat less. Patients start on a low dose thats gradually increased each week. Schmidt says some people may not respond to the lower doses but do eventually see weight loss as the medication is ramped up.

Without lifestyle changes, these medications are likely to be less effective for weight loss. Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound, stress that the drugs are meant to be used alongside a healthy diet and exercise. In trials of semaglutide and tirzepatide, the medications were paired with a reduced-calorie diet and increased physical activity. Clinical trials are often the best-case scenario when it comes to a drugs efficacy because they involve careful tracking of participants and many follow-up visits with providers. In real life, patients may not follow their weight-loss plan as diligently or see their doctor as regularly.

And while these drugs help curb appetite, they dont magically eliminate all temptations. After all, there is a major social component to eating food. We may eat because it looks good, tastes good, were in the company of others, or because its available, Rothberg says. A person who has those environmental pushes or stimuli competing with the drug wont lose as much weight as the person who doesnt have to deal with those factors, she argues.

Differences in metabolism, or how people break down food and convert it into energy, could also be at play. A persons age and hormone function, as well as the amount of physical activity they get, can have an effect on metabolism.

Researchers are also looking into whether genetic factors may explain some of the variability in response. In 2022, Pearson and his colleagues published a paper that identified a gene called ARRB1 that seems to be involved in glucose control. When they looked at genetic data from more than 4,500 adults, they found that people with certain variants in this gene have lower blood sugar levels while taking GLP-1 drugs.

Read more:
Not Everyone Loses Weight on Ozempic - WIRED

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker